Are These the Best Big Biotech Stocks for Your Portfolio?

Gilead Sciences  (NASDAQ: GILD  ) has had a banner year.

Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations.

Celgene  (NASDAQ: CELG  ) has had a more mixed experience this year, with concerns about the Revlimid patent and even some less-than-stellar trial data for its up-and-coming drug Otezla.

But Gilead's opportunity is more than just Sovaldi, and Celgene's is more than just Revlimid (and even more than just Revlimid and Otezla).

Are they the best big biotechs?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.

Leaked: This coming blockbuster will make even Gilead and Celgene jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 3025098, ~/Articles/ArticleHandler.aspx, 7/31/2014 10:04:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement